GeneDx Holdings Corp (WGS)

Currency in USD
34.71
+0.20(+0.58%)
Closed·
34.26-0.45(-1.30%)
·
Unusual trading volume
Trading near 52-week Low
WGS is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
32.2135.94
52 wk Range
32.21170.87
Key Statistics
Prev. Close
34.51
Open
34.4
Day's Range
32.21-35.94
52 wk Range
32.21-170.87
Volume
4.23M
Average Volume (3m)
983.04K
1-Year Change
-39.4663%
Book Value / Share
8.68
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
WGS Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
85.89
Upside
+147.45%
Members' Sentiments
Bearish
Bullish
ProTips
6 analysts have revised their earnings downwards for the upcoming period

GeneDx Holdings Corp News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Analyst Ratings

9 Buy
0 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 85.89
(+147.45% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Craig-Hallum
Buy85.00+144.89%153.00MaintainMay 05, 2026
Wells Fargo
Buy75.00+116.08%155.00MaintainMay 05, 2026
TD Cowen
Buy55.00+58.46%90.00MaintainMay 05, 2026
Guggenheim
Buy70.00+101.67%100.00MaintainMay 05, 2026
Canaccord
Buy75.00+116.08%100.00MaintainMay 05, 2026

GeneDx Holdings Corp Earnings Call Summary for Q1/2026

  • GeneDx Q1 2026 EPS of -$0.28 missed forecast of -$0.01; revenue $102.3M fell short of expected $112.45M by $10.15M.
  • Volume growth strong at 34% YoY for exome/genome testing; adjusted gross margin maintained at 69% despite revenue pressures.
  • Full-year 2026 revenue guidance cut 12% to $475-490M; company expects return to adjusted profitability with 30%+ volume growth.
  • Implementing $25M operational cost reductions; strategic focus on whole genome sequencing transition to drive long-term growth.
  • Stock rose 0.69% premarket to $65.83 despite earnings miss; analysts forecast FY2026 EPS of $0.89 vs. -$0.73 LTM loss.
Last Updated: 2026-05-04, 05:46 p/m
Read Full Transcript

Earnings

Latest Release
May 04, 2026
EPS / Forecast
-0.28 / -0.01
Revenue / Forecast
102.3M / 112.45M
EPS Revisions
Last 90 days

WGS Income Statement

Compare WGS to Peers and Sector

Metrics to compare
WGS
Peers
Sector
Relationship
P/E Ratio
−13.2x−29.5x−0.5x
PEG Ratio
−0.78−0.340.00
Price/Book
4.0x3.0x2.6x
Price / LTM Sales
2.3x2.3x3.2x
Upside (Analyst Target)
146.3%40.6%47.8%
Fair Value Upside
Unlock11.2%5.9%Unlock

GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
10.38M35.43%358.12M
Other Institutional Investors
28.37M64.57%978.89M
Public Companies & Retail Investors
0.000.00%0.00
Total
38.74M100.00%1.34B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Corvex Management LP11.02%3,228,150111,403
Casdin Capital, LLC10.27%3,007,164103,777

People Also Watch

2.305
ALLO
+6.22%
87.81
SKYW
+5.52%
20.45
OPCH
-3.99%
3.56
EMBC
-8.72%

FAQ

What Is the GeneDx Holdings (WGS) Stock Price Today?

The GeneDx Holdings stock price today is 34.71 USD.

What Stock Exchange Does GeneDx Holdings Trade On?

GeneDx Holdings is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for GeneDx Holdings?

The stock symbol for GeneDx Holdings is "WGS."

What Is the GeneDx Holdings Market Cap?

As of today, GeneDx Holdings market cap is 1.02B USD.

What Is GeneDx Holdings's Earnings Per Share (TTM)?

The GeneDx Holdings EPS (TTM) is -0.73.

When Is the Next GeneDx Holdings Earnings Date?

GeneDx Holdings will release its next earnings report on Aug 17, 2026.

From a Technical Analysis Perspective, Is WGS a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has GeneDx Holdings Stock Split?

GeneDx Holdings has split 1 times.

How Many Employees Does GeneDx Holdings Have?

GeneDx Holdings has 1300 employees.

What is the current trading status of GeneDx Holdings (WGS)?

As of May 07, 2026, GeneDx Holdings (WGS) is trading at a price of 34.71 USD, with a previous close of 34.51 USD. The stock has fluctuated within a day range of 32.21 USD to 35.94 USD, while its 52-week range spans from 32.21 USD to 170.87 USD.

What Is GeneDx Holdings (WGS) Price Target According to Analysts?

The average 12-month price target for GeneDx Holdings is 85.89 USD, with a high estimate of 130 USD and a low estimate of 55 USD. 9 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +147.45% Upside potential.

What Is the WGS Premarket Price?

WGS's last pre-market stock price is 34.59 USD. The pre-market share volume is 70,510.00, and the stock has decreased by 0.08, or 0.23%.

What Is the WGS After Hours Price?

WGS's last after hours stock price is 34.26 USD, the stock has decreased by -0.45, or -1.30%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.